SOURCE: INC Research

INC Research

March 28, 2011 12:49 ET

INC Research Releases Paper on Latest Trends in Networked Drug Development

Paper Offers Insight into How Sponsors Can Develop More of Their Pipeline With Less Risk

RALEIGH, NC--(Marketwire - March 28, 2011) - INC Research, LLC, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, today announced it has released a new white paper entitled, "Win with Networked Drug Development Alliances: New Strategies to Increase Productivity and Mitigate Risk." A sequel to its earlier white paper on clinical delivery alliances, INC Research's new paper reviews the latest trends in strategic drug development partnerships and offers a proven approach to increasing pipeline productivity with less risk.

Large biopharms are caught between two powerful market forces: the pressure to maximize profits and the need for continual investment in their drug pipelines. For drug development executives, choosing which drugs to commercialize is all about trade-offs -- such as passing over numerous pre-clinical compounds to aggressively pursue the highest probability clinical trials, maximizing the likelihood of achieving near-term revenue and earnings needs. Executives know that letting go of promising compounds could mean missing their next big hit. This paper explores the challenges drug development executives face in maximizing the return of their drug pipeline and reveals the many benefits of networked drug development.

INC Research is at the forefront of creating a networked model in which sponsors, investors, CROs, and other service providers all work in strategic partnership to improve the speed, efficiency, and quality of drug development. Having created a team focused solely on structuring and managing successful alliance relationships, INC Research is uniquely positioned to build these partnerships by maintaining a robust network of therapeutically focused investors that understand the uniqueness of pharmaceutical investments. By building a networked drug development alliance, INC Research offers its clients access to outside R&D funding without disrupting existing programs.

To download a copy of "Win with Networked Drug Development Alliances: New Strategies to Increase Productivity and Mitigate Risk," visit www.incresearch.com/networked. The paper will also be available at this week's Partnerships in Clinical Trials conference in Phoenix, Arizona at INC Research's booth #501.

About INC Research, LLC.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com or follow us at @inc_research.

Contact Information